Where Will Mereo BioPharma Group plc - ADR (MREO) Stock Go Next After It Is Higher By 9.42% in a Week?

Overall market sentiment has been high on Mereo BioPharma Group plc - ADR (MREO) stock lately. MREO receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Mereo BioPharma Group plc - ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MREO!

See Full MREO Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With MREO Stock Today?

Mereo BioPharma Group plc - ADR (MREO) stock is lower by -3.53% while the S&P 500 has risen 0.06% as of 10:37 AM on Monday, Sep 18. MREO has fallen -$0.05 from the previous closing price of $1.56 on volume of 248,166 shares. Over the past year the S&P 500 has risen 14.18% while MREO has risen 51.00%. MREO lost -$0.35 per share in the over the last 12 months.

More About Mereo BioPharma Group plc - ADR

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Click Here to get the full Stock Report for Mereo BioPharma Group plc - ADR stock.